- Trials with a EudraCT protocol (10,655)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (712)
10,655 result(s) found for: cancer.
Displaying page 95 of 533.
EudraCT Number: 2011-003062-32 | Sponsor Protocol Number: B1271004 | Start Date*: 2011-12-20 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A RANDOMIZED PHASE 2 NON-COMPARATIVE STUDY OF THE EFFICACY OF PF-04691502 AND PF-05212384 IN PATIENTS WITH RECURRENT ENDOMETRIAL CANCER | |||||||||||||
Medical condition: RECURRENT ENDOMETRIAL CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) ES (Completed) PL (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004481-15 | Sponsor Protocol Number: ETOP2-11/MO27911 | Start Date*: 2012-06-21 | |||||||||||
Sponsor Name:ETOP (European Thoracic Oncology Platform) | |||||||||||||
Full Title: An open-label phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations | |||||||||||||
Medical condition: Advanced NSCLC harbouring EGFR mutations (del19 or L858R). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IE (Completed) FR (Completed) GR (Completed) GB (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001416-23 | Sponsor Protocol Number: FM-B07-01 | Start Date*: 2007-08-31 | |||||||||||
Sponsor Name:FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI | |||||||||||||
Full Title: A Multinational Double-Blind, Randomized Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and... | |||||||||||||
Medical condition: Patients with Locally Recurrent or Metastatic Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000348-28 | Sponsor Protocol Number: BO15943 | Start Date*: 2007-08-30 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors. | ||
Medical condition: To continue to provide treatment to those patients that may still be on treatment at the moment of the final data base closure/clinical cut-off of a clinical trials in which Herceptin® is investiga... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) PT (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003687-36 | Sponsor Protocol Number: ICORG1502 | Start Date*: 2015-12-04 | ||||||||||||||||
Sponsor Name:Cancer Trials Ireland CLG | ||||||||||||||||||
Full Title: Phase IB/II clinical trial of copanlisib in combination with trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer | ||||||||||||||||||
Medical condition: HER2 positive metastatic or recurrent breast cancer, following disease progression during, or after, treatment with at least one treatment regimen in the metastatic or recurrent setting. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002474-39 | Sponsor Protocol Number: VBN-01 | Start Date*: 2018-01-17 | |||||||||||||||||||||||||||||||
Sponsor Name:Nykode Therapeutics AS | |||||||||||||||||||||||||||||||||
Full Title: An open-label first-in-human phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO or VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy... | |||||||||||||||||||||||||||||||||
Medical condition: Locally advanced or metastatic solid tumours including melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or SCCHN | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-002464-27 | Sponsor Protocol Number: IEOS707/412 | Start Date*: 2013-06-26 | ||||||||||||||||||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | ||||||||||||||||||||||||||||
Full Title: Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients with solid tumors metastatic or relapsed, resistant/refractory to conventional therapy, using HLA-identical related donors or H... | ||||||||||||||||||||||||||||
Medical condition: solid tumors metastatic or relapsed, resistant/refractory to conventional therapy | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001496-20 | Sponsor Protocol Number: ISRCTN43372330 | Start Date*: 2008-06-06 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Breakthrough Breast Cancer & Cancer Research UK Genetic Breast Cancer Trial: A randomised phase II pilot trial of carboplatin compared to docetaxel for patients with metastatic genetic breast can... | |||||||||||||
Medical condition: Metastatic breast cancer in women with BRCA1 or BRCA 2 mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: PT (Completed) SE (Ongoing) ES (Ongoing) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002241-37 | Sponsor Protocol Number: 2006/VCC/0039 (WCTU01) | Start Date*: 2007-04-17 | |||||||||||
Sponsor Name:Velindre NHS Trust | |||||||||||||
Full Title: A randomised phase II/III multi-centre clinical trial of definitive chemo-radiaiton, with or without cetuximab, in carcinoma of the oesophagus | |||||||||||||
Medical condition: in-operable carcinoma of the oesophagus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000871-13 | Sponsor Protocol Number: EMD72000-035 | Start Date*: 2006-08-09 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Phase I/II, Open Label, Dose-Escalating Study Evaluating the Safety and Efficacy of the Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody EMD 72000 (Matuzumab) in Combination with ... | |||||||||||||
Medical condition: Stage IIIB/IV non-small cell lung cancer and progressive disease after first-line treatment with a platinum analogue in comination with taxanes, gemcitabine, or vinorelbine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003340-45 | Sponsor Protocol Number: TRUST | Start Date*: 2012-02-23 | |||||||||||
Sponsor Name:ARCO | |||||||||||||
Full Title: OPEN-LABEL PHASE II STUDY OF INDUCTION TREATMENT WITH FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY PREOPERATIVE CHEMORADIOTHERAPY PLUS BEVACIZUMAB IN PATIENTS WITH LOCALLY ADVANCED, RESECTABLE RECTAL CANCER | |||||||||||||
Medical condition: Advanced Rectal Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014773-40 | Sponsor Protocol Number: AVASTEM/IPC2009-001 | Start Date*: 2010-01-04 | |||||||||||
Sponsor Name:Institut Paoli-Calmettes | |||||||||||||
Full Title: Essai de phase II de preuve du concept : Evaluation de l’activité anti-cellules souches cancéreuses du bevacizumab administré en combinaison à la chimiothérapie néoadjuvante dans les cancers du sein | |||||||||||||
Medical condition: Tumeurs du sein localement avancées ou inflammatoires candidates à un traitement néo-adjuvant par une association séquentielle FEC/docetaxel . | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005827-32 | Sponsor Protocol Number: TIE | Start Date*: 2006-05-10 | |||||||||||
Sponsor Name:Verein zur Förderung der Pneumologie am Krankenhaus Großhansdorf e.V. | |||||||||||||
Full Title: Offene, randomisierte, multizentrische Phase-II-Studie zum Vergleich der Wirksamkeit und Verträglichkeit von Erlotinib vs Carboplatin/Vinorelbin bei Patienten mit unvorbehandeltem nicht-kleinzellig... | |||||||||||||
Medical condition: non-pretreated advanced non-small-cell lung cancer in elderly patients (≥70 years) | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008739-27 | Sponsor Protocol Number: ML21868 | Start Date*: 2009-08-17 | |||||||||||
Sponsor Name:ROCHE | |||||||||||||
Full Title: Randomised phase II trial of bevacizumab (AVASTIN) in combination with gemcitabine or attenuated doses of cisplatin and gemcitabine as first-line treatment of elderly patients with advanced, metast... | |||||||||||||
Medical condition: Locally advanced (Stage IIIb with supraclavicular lymph node metastases or malignant pleural or pericardial effusion) or metastatic (Stage IV) non-squamous non small cell lung cancer (NSCLC). | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005173-56 | Sponsor Protocol Number: GOG/2007-01 | Start Date*: 2008-03-06 | |||||||||||
Sponsor Name:Grupo Oncológico Gallego (GOG) | |||||||||||||
Full Title: ENSAYO CLÍNICO ABIERTO, NO ALEATORIZADO, EN FASE II, DE TRATAMIENTO SECUENCIAL CON TAXOTERE® (T) SEGUIDO DE MYOCET® Y CICLOFOSFAMIDA (MC), COMO TRATAMIENTO ANTINEOPLASICO PRIMARIO EN PACIENTES CON ... | |||||||||||||
Medical condition: Cáncer de mama localizado (estadio II y IIIa). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001825-32 | Sponsor Protocol Number: TTD-08-02 | Start Date*: 2008-07-01 | |||||||||||
Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD) | |||||||||||||
Full Title: "Fase II Docetaxel-Oxiplatino-Capecitabina (DOX) a dosis ajustadas en pacientes con adenocarcinoma gástrico avanzado y estado general subóptimo" | |||||||||||||
Medical condition: Pacientes diagnosticados histológicamente de adenocarcinoma gástrico o de la unión esófago gástrica (tipos I, II y III de Siewert) localmente avanzado irresecable, metastásico o recidivado. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005534-55 | Sponsor Protocol Number: local/2014/LMb-01bis | Start Date*: 2015-07-24 | |||||||||||
Sponsor Name:CHU de Nîmes | |||||||||||||
Full Title: Etude de la variabilité pharmacocinétique du sunitinib chez les patients atteints de cancer du rein métastatique: recherche de déterminants pharmacogénétiques | |||||||||||||
Medical condition: CANCER DU REIN | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007027-40 | Sponsor Protocol Number: 0205-1isni07 / 001.112 | Start Date*: 2008-03-07 | |||||||||||
Sponsor Name:Centre Georges-François Leclerc | |||||||||||||
Full Title: A Multicenter open-label, phase I/II dose escalation study of oral lapatinib in combination with docetaxel in patients with HER2 positive advanced or metastatic breast cancer | |||||||||||||
Medical condition: HER 2 positive advanced or metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016932-11 | Sponsor Protocol Number: 15051982 | Start Date*: 2010-03-08 | ||||||||||||||||
Sponsor Name:BOOG Study Center B.V | ||||||||||||||||||
Full Title: Phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative breast cancer. | ||||||||||||||||||
Medical condition: Patients with locally advanced or large resectable HER2-negative breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022793-14 | Sponsor Protocol Number: AB10007 | Start Date*: 2011-08-05 | ||||||||||||||||
Sponsor Name:AB Science | ||||||||||||||||||
Full Title: A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU) or capecitabine, or masi... | ||||||||||||||||||
Medical condition: gastric or gastro-oesophageal junction metastatic adenocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
